Skip to main content

Tirzepatide vs Survodutide

Both Tirzepatide and Survodutide are used for weight-loss and metabolic. Here's how their evidence, dosing, and regulatory status actually compare.

Tirzepatide

Evidence A+

Tirzepatide (Mounjaro / Zepbound)

A dual GIP/GLP-1 receptor agonist that achieved up to 22.5% mean weight loss in the SURMOUNT-1 trial — the highest of any FDA-approved weight loss medication.

View full Tirzepatide profile →

Survodutide

Evidence A

Survodutide (BI 456906)

A dual GLP-1 / glucagon receptor agonist with strong Phase 2 weight-loss and MASH data. Resolution of MASH in 83% of participants at the highest dose at week 48.

View full Survodutide profile →

Side-by-Side

AttributeTirzepatideSurvodutide
Evidence GradeA+A
FDA StatusFDA-approved for weight management and type 2 diabetesNot FDA-approved — Phase 3 trials for obesity and MASH
Typical Dose2.5–15 mg weekly (subcutaneous injection)Trial range: 0.6–6 mg weekly (subcutaneous)
Clinics Indexed1,8506
Categoriesweight-loss, metabolicweight-loss, metabolic

Key reported benefits — Tirzepatide

  • Superior weight loss
  • Dual hormone targeting
  • Blood sugar control
  • Reduced cardiovascular risk

Key reported benefits — Survodutide

  • Weight loss
  • MASH resolution
  • Glucose control

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons